1 Biotech Acquisition Company Receivables Turnover Ratio (BIOT), from the third quarter 2022 to the third quarter 2021 current and historic results, rankings and more - CSIMarket

Company Name, Ticker, Suppliers, else..

Growth Rates

Profitability

Valuation Comparisons

Management Effectiveness

Financial Strength

Efficiency

• Sales per Employee

• Income per Employee

• Inventory Turnover

• Asset Turnover

• Receivables Turnover

Dividend Comparisons

Biotech Acquisition Company (NASDAQ: BIOT)

Sector • Financial Industry • Blank Checks

Industry • Blank Checks

Sector • Financial

Biotech Acquisition Accounts Receivables Turnover Ratio from the third quarter 2022 to the third quarter 2021

Quarterly Results, Trends, Rankings, Statistics

According to Biotech Acquisition Company Balance Sheet, in the third quarter 2022, company has not reported any Accounts receivable.
See Biotech Acquisition Company Balance Sheet

If we take a look into Financial sector Biotech Acquisition Company achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Biotech Acquisition Company Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BIOT Receivables Turnover Ratio	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter
Y / Y Receivable Change	-	-	-	-	-
Y / Y Revenue Change	-	-	-	-	-
Receivable Turnover Ratio (TTM)	-	-	-	-	-
BIOT's Total Ranking	#	#	#	#	#
Accounts Receivable average collection period days	-	-	-	-	-
Seq. Receivable Change	-	-	-	-	-
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Blank Checks Industry	#
Financial Sector	#
Overall Market	#

Receivable Turnover Ratio Statistics
High	Average	Low
0	0	0

BIOT Company Profile • Back to BIOT Efficiency Comparisons • Compare BIOT Receivables Turnover Ratio to its Competitors

Financial Statements
Biotech Acquisition's Accounts Receivable	$ 0 Millions	Visit BIOT's Balance sheet
Biotech Acquisition's Sales TTM	$ 0 Millions	Visit BIOT's Income Statement
Sources of BIOT's Revenues		Visit BIOT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Blank Checks Industry Accounts Receivable Turnover Trends and Statistics
Financial Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
BIOT's Receivable Turnover Ratio versus Blank Checks Industry, Financial Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
BIOT's Growth Rates	BIOT's Roa	BIOT's Inventory Turnover Ratio	BIOT's Dividend Comparisons
BIOT's Profitability Ratios	BIOT's Roi	BIOT's Asset Turnover Ratio	BIOT's Dividend Growth
BIOT's Valuation Ratios	BIOT's Roe	BIOT's Financial Strength Ratios	BIOT's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2022, within Financial Sector

Receivable Turnover Ratio

Revenues for 12 Months ending Sep 30 2022

Receivable at quarter ending Sep 30 2022

Date modified: 2026-06-22T16:30:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.